The global forage feed market has been undergoing noteworthy development in the past few years. This can be accredited to the progression in farm animal production, upsurge in the global meat intake, and growing awareness regar…
BMI View: Israel will continue to be targeted by multinational drugmakers as a destination for innovative
drug sales; however, their relative success will be limited by funding constraints towards the country's
health services basket and the lack of transparency with new drug inclusions. An uptick in economic growth
and an increase to government funding supports our moderate growth outlook for Israel's pharmaceuticals
and healthcare sectors over the coming years.
Headline Expenditure Projections
- Pharmaceuticals: ILS7.82bn (USD2.01bn) in 2015 to ILS8.15bn (USD2.11bn) in 2016; +4.2% in local
currency terms and +4.6% in US dollar terms. Forecast in line with Q316.
- Healthcare: ILS88.95bn (USD22.90bn) in 2015 to ILS93.61bn (USD24.19bn) in 2016; +5.2% in local
currency terms and +5.6% in US dollar terms. Forecast downgraded from Q316.